Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Income from Continuing Operations (2021 - 2025)

InMed Pharmaceuticals' Income from Continuing Operations history spans 5 years, with the latest figure at 2028223.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 21.23% year-over-year to 2028223.0; the TTM value through Dec 2025 reached 7664363.0, up 3.06%, while the annual FY2025 figure was 8162133.0, 6.34% down from the prior year.
  • Income from Continuing Operations reached 2028223.0 in Q4 2025 per INM's latest filing, down from 1726899.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 336591.0 in Q2 2023 to a low of 7870023.0 in Q2 2022.
  • Average Income from Continuing Operations over 5 years is 2562619.11, with a median of 2063155.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: surged 95.72% in 2023, then plummeted 473.57% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 4282814.0 in 2021, then soared by 51.01% to 2098087.0 in 2022, then grew by 29.55% to 1478185.0 in 2023, then tumbled by 74.2% to 2575024.0 in 2024, then grew by 21.23% to 2028223.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Income from Continuing Operations are 2028223.0 (Q4 2025), 1726899.0 (Q3 2025), and 1788311.0 (Q2 2025).